Support PoliticusUSA’s ad-free and fearless journalism by becoming a subscriber.
In a rather theatrical display, Trump has been orchestrating a complex shell game with the markets regarding tariffs, seemingly attempting to stave off economic downturns and negative press. Late last Friday, reports emerged indicating that certain exemptions would be granted for chips and electronics.
However, just two days later, Trump’s Commerce Secretary reversed that narrative, announcing that the administration intends to implement a specialized tariff on prescription drugs within the next month or two.
Video:
According to a transcript from ABC’s This Week:
“Over the past couple of months, President Trump has targeted pharmaceuticals, semiconductors, and the auto industry, labeling them as sectors subject to non-negotiable tariffs. This is part of a broader strategy to ensure that essential national security products are manufactured domestically. The COVID-19 pandemic underscored the necessity for America to produce its own medicine and semiconductors. Nearly all semiconductors are currently produced in Taiwan and finished in China. It’s critical to bring that production back to the U.S.”
“The president will soon announce policies regarding semiconductors and pharmaceuticals, which will be treated distinctly from the reciprocal tariffs, implying a unique set of considerations for these products.”
KARL: “But hold on, I’m trying to clarify the exemption about the notice from Friday that stated a variety of electronics, including smartphones and microchip components, would now be exempt from the reciprocal tariffs. Why that shift?”
LUTNICK: “These products will fall under the upcoming semiconductor sectoral tariffs. Expect an official notice in the federal registry this week.”
“Similar processes were applied to autos. The president will also extend this to pharmaceuticals, ensuring that these industries receive targeted tariffs aimed at restoring domestic production.”
However, the reality is that companies cannot simply uproot factories and relocate them to the United States overnight. Such transitions are lengthy, often taking years to materialize. By the time any actual shifts occur, the Trump administration may very well be history—leaving these policies as mere footnotes in economic history. Companies have two choices: they can relocate production to low-tariff regions or pass on the costs to American consumers.
This means that Trump’s proposed tariffs on prescription drugs may very well lead to increased costs for life-saving medications, directly impacting the health of Americans who rely on them.
While the media has been preoccupied with the rising costs of electronics, it’s worth noting that not everyone is in the market for the latest gadget. However, when the prices of antibiotics, cancer treatments, or diabetes medications surge, the ramifications for the American populace are profound. Health insurance providers may respond to these price increases by raising co-pays or cutting back on coverage.
What Lutnick discussed was essentially a tax on prescription drugs. While this may seem trivial to the affluent elite and billionaires surrounding Trump, for many Americans, it could spell the difference between life and death.
What are your thoughts on the proposed tariff on prescription drugs? We invite you to share your insights in the comments below.
